-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)
StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)
Investment analysts at StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a research note issued to investors on Friday. The brokerage set a "buy" rating on the stock.
Separately, TheStreet cut shares of Trinity Biotech from a "c-" rating to a "d" rating in a research report on Tuesday, July 5th.
Get Trinity Biotech alerts:Trinity Biotech Trading Down 5.1 %
Shares of TRIB opened at $1.16 on Friday. The stock has a market capitalization of $31.16 million, a P/E ratio of -2.27 and a beta of 1.33. The firm's fifty day simple moving average is $1.35 and its two-hundred day simple moving average is $1.22. Trinity Biotech has a 12 month low of $0.86 and a 12 month high of $3.05.
Trinity Biotech (NASDAQ:TRIB – Get Rating) last issued its quarterly earnings results on Thursday, June 30th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $18.78 million for the quarter. Trinity Biotech had a negative net margin of 15.10% and a negative return on equity of 347.92%.Hedge Funds Weigh In On Trinity Biotech
Several large investors have recently added to or reduced their stakes in TRIB. Atria Wealth Solutions Inc. bought a new position in Trinity Biotech in the 1st quarter valued at about $27,000. Virtu Financial LLC bought a new position in Trinity Biotech in the 1st quarter valued at about $40,000. Whitefort Capital Management LP bought a new position in Trinity Biotech in the 4th quarter valued at about $50,000. Envestnet Asset Management Inc. bought a new position in Trinity Biotech in the 4th quarter valued at about $159,000. Finally, Highbridge Capital Management LLC purchased a new stake in Trinity Biotech in the 1st quarter valued at about $1,221,000. Institutional investors own 27.11% of the company's stock.
Trinity Biotech Company Profile
(Get Rating)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Recommended Stories
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
Investment analysts at StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a research note issued to investors on Friday. The brokerage set a "buy" rating on the stock.
斯托克新闻网的投资分析师在周五发布给投资者的一份研究报告中对利邦生物科技(纳斯达克：TRIB-GET评级)的股票进行了报道。该经纪公司对该股设定了“买入”评级。
Separately, TheStreet cut shares of Trinity Biotech from a "c-" rating to a "d" rating in a research report on Tuesday, July 5th.
另外，华尔街在7月5日星期二的一份研究报告中将利邦生物科技的股票评级从“c-”下调至“d”。
Trinity Biotech Trading Down 5.1 %
利邦生物科技股价下跌5.1%
Shares of TRIB opened at $1.16 on Friday. The stock has a market capitalization of $31.16 million, a P/E ratio of -2.27 and a beta of 1.33. The firm's fifty day simple moving average is $1.35 and its two-hundred day simple moving average is $1.22. Trinity Biotech has a 12 month low of $0.86 and a 12 month high of $3.05.
Trib的股票周五开盘报1.16美元。该股市值为3,116万美元，市盈率为-2.27，贝塔系数为1.33。该公司的50日简单移动均线切入位为1.35美元，200日简单移动均线切入位为1.22美元。利邦生物科技的12个月低点为0.86美元，12个月高位为3.05美元。
Hedge Funds Weigh In On Trinity Biotech
对冲基金入股利邦生物科技
Several large investors have recently added to or reduced their stakes in TRIB. Atria Wealth Solutions Inc. bought a new position in Trinity Biotech in the 1st quarter valued at about $27,000. Virtu Financial LLC bought a new position in Trinity Biotech in the 1st quarter valued at about $40,000. Whitefort Capital Management LP bought a new position in Trinity Biotech in the 4th quarter valued at about $50,000. Envestnet Asset Management Inc. bought a new position in Trinity Biotech in the 4th quarter valued at about $159,000. Finally, Highbridge Capital Management LLC purchased a new stake in Trinity Biotech in the 1st quarter valued at about $1,221,000. Institutional investors own 27.11% of the company's stock.
几家大型投资者最近增持或减持了Trib的股份。Atria Wealth Solutions Inc.在第一季度购买了利邦生物科技的一个新头寸，价值约为27,000美元。Virtu Financial LLC在第一季度购买了利邦生物科技的一个新头寸，价值约为4万美元。怀特福德资本管理公司在第四季度购买了利邦生物科技的一个新头寸，价值约5万美元。Envestnet Asset Management Inc.在第四季度购买了利邦生物科技的一个新头寸，价值约15.9万美元。最后，Highbridge Capital Management LLC在第一季度收购了利邦生物科技的新股份，价值约1221,000美元。机构投资者持有该公司27.11%的股份。
Trinity Biotech Company Profile
利邦生物科技公司简介
(Get Rating)
(获取评级)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
利邦生物技术公司为美洲、非洲、亚洲和欧洲的诊断市场的临床实验室和护理点(POC)细分市场收购、开发、制造和营销医疗诊断产品。该公司提供临床实验室产品，包括诊断测试和仪器，用于检测传染病，如莱姆病；由梅毒和疱疹组成的性传播疾病；SARS-CoV-2；以及爱泼斯坦巴尔病毒、麻疹、腮腺炎、弓形体病、巨细胞病毒、风疹、水痘和其他病毒病原体，以及用于监测和诊断糖尿病并识别有糖尿病风险的人的血红蛋白A1c体外诊断测试的产品。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
- 免费获取StockNews.com关于利邦生物科技的研究报告(Trib)
- 耐克股票会被超卖，但仍被高估吗？
- 美国铝业是在第二季度业绩强劲和更多股票回购之后买入的吗？
- 皇家加勒比的宽带合作能否推动收入增长？
- 芯片设备制造商Entigis很有潜力，但它现在可以买下吗？
- DocuSign在报告收益时有重要的问题需要解决
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
获得《利邦生物科技日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对利邦生物科技和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧